These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 9659838)

  • 1. [Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity].
    Svendsen TL; Ingerslev J; Mørk A
    Ugeskr Laeger; 1998 Jun; 160(27):4073-5. PubMed ID: 9659838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is an ephedrine caffeine treatment contraindicated in hypertension?
    Ingerslev J; Svendsen TL; Mørk A
    Int J Obes Relat Metab Disord; 1997 Aug; 21(8):666-73. PubMed ID: 15481766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
    Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function.
    Barenbrock M; Colmorgen U; Firschka E; Gellert J; Lippert J; Schröder K; Spieker C; Voigt-Ladner G; Wagner K; Neumayer HH
    Clin Nephrol; 1995 Jun; 43(6):388-91. PubMed ID: 7554523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.
    Astrup A; Breum L; Toubro S; Hein P; Quaade F
    Int J Obes Relat Metab Disord; 1992 Apr; 16(4):269-77. PubMed ID: 1318281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HMG-CoA reductase inhibitors on blood pressure in hypertensive patients treated with blood pressure-lowering agents: retrospective study using an anti-hypertensive drug database.
    Hashimoto S; Urushihara H; Hinotsu S; Kosugi S; Kawakami K
    Eur Rev Med Pharmacol Sci; 2012 Feb; 16(2):235-41. PubMed ID: 22428476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does pseudoephedrine increase blood pressure in patients with controlled hypertension?
    Coates ML; Rembold CM; Farr BM
    J Fam Pract; 1995 Jan; 40(1):22-6. PubMed ID: 7807033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
    Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
    Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects].
    Kawasaki T; Jun CJ; Fukushima Y; Kegai K; Seki E; Osajima K; Itoh K; Matsui T; Matsumoto K
    Fukuoka Igaku Zasshi; 2002 Oct; 93(10):208-18. PubMed ID: 12471719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.
    Dahlöf B; Jönsson L; Borgholst O; Ekblad G; Engstrand C; Grundestam I; Lindh A
    Blood Press Suppl; 1993; 1():37-45. PubMed ID: 8173689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
    J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.